Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 6/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 6/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21205744 | 0.86 | KMT2A (0.43) | KMT2ASMN1; SMN2CYSLTR2CYSLTR1 | |
| SCHEMBL1007881 | 0.86 | SLC22A12 (0.44) | KMT2ASMN1; SMN2CYSLTR2CYSLTR1 | |
| SCHEMBL957166 | 0.86 | SLC22A12 (0.44) | KMT2ASMN1; SMN2CYSLTR2CYSLTR1 | |
| SCHEMBL11436469 | 0.78 | L3MBTL1 (0.62) | LMNA | |
| SCHEMBL11436413 | 0.78 | L3MBTL1 (0.62) | LMNA | |
| SCHEMBL11436414 | 0.78 | L3MBTL1 (0.62) | LMNA | |
| SCHEMBL10635784 | 0.76 | CYSLTR1 (0.74) | KMT2ASMN1; SMN2CYSLTR2CYSLTR1MAPK1 | |
| SCHEMBL2185411 | 0.75 | MAPK1 (0.41) | KMT2ASMN1; SMN2CYSLTR2CYSLTR1MAPK1 | |
| SCHEMBL19291551 | 0.75 | OPRK1 (0.42) | KMT2ASMN1; SMN2CYSLTR2CYSLTR1MAPK1 | |
| SCHEMBL1760752 | 0.75 | HPGD (0.48) | CYP1A2CYP2C19ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947735-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-05-24 | — | — | US | claimed |
| CN-101374415-A | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORP (US) | 2009-02-25 | — | — | CN | claimed |
| US-20080306150-A1 | Compounds for the Treatment of Metabolic Disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-12-11 | — | — | US | claimed |
| EP-1976378-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2008-10-08 | — | — | EP | claimed |
| WO-2007087506-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-08-02 | — | — | WO | claimed |
| US-7947735-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-05-24 | — | — | US | disclosed |
| CN-101374415-A | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORP (US) | 2009-02-25 | — | — | CN | disclosed |
| US-20080306150-A1 | Compounds for the Treatment of Metabolic Disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1976378-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007087506-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306150-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FABP1, CPT1B | KMT2A 2650/4885SMN1; SMN2 2328/4885CYSLTR2 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.